FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Назад в Научную Библиотеку
PubMedReviewЧеловеческие Субъекты

The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.

Nauck Michael A, Quast Daniel R, Wefers Jakob, Pfeiffer Andreas F H
Diabetes, obesity & metabolism2021DOI: 10.1111/dom.14496
GIPGLP-1

Качественный Балл

7/10

Цитирования

0

Объекты Исследования

Человеческий

Анализ Peptide Contacts

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for GIP, GLP-1 are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for GIP, GLP-1. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Ключевые Найденные Результаты

The review highlights the roles of GIP and GLP-1 in glucose homeostasis, insulin secretion, and their potential therapeutic benefits for metabolic and cardiovascular diseases. It also discusses the reduced incretin effect in type 2 diabetes and the superior efficacy of co-agonists targeting both receptors.

Ограничения

As a review paper, it relies on existing literature which may not cover all recent findings or experimental nuances. The clinical relevance is based on previous studies with varying methodologies.

Как интерпретировать эту исследовательскую работу

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Анализ Peptide Contacts

Highlighting the evolving understanding of GIP and GLP-1 in metabolic diseases and their therapeutic implications.

GIPGLP-1

The Dual Role of GIP and GLP-1 in Metabolic Health: A Closer Look

Published: May 17, 2026 | Source: Diabetes, obesity & metabolism (2021) | Category: GIP, GLP-1

Overview

This review paper delves into the roles of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in metabolic health, focusing on their effects on glucose homeostasis and potential therapeutic benefits for type 2 diabetes and cardiovascular disease. The findings highlight the diminished incretin effect in patients with type 2 diabetes and suggest that co-agonists targeting both GIP and GLP-1 receptors may offer superior efficacy.

Study Background

Incretins, particularly GIP and GLP-1, have been recognized for their critical role in enhancing insulin secretion after meals. Prior research established the importance of these peptides in maintaining normal glucose tolerance through their interaction with pancreatic beta cells. However, the specific mechanisms by which GIP and GLP-1 contribute to metabolic health and potential therapeutic benefits were not fully understood. This review aims to provide a comprehensive update on recent findings regarding these incretins.

What the Research Found

The study reveals that both GIP and GLP-1 play significant roles in glucose homeostasis, with additive effects on insulin secretion. However, their functions diverge when it comes to glucagon regulation: GLP-1 suppresses glucagon release while GIP increases it, both actions being glucose-dependent. Importantly, the review highlights that type 2 diabetic patients exhibit a reduced incretin effect despite normal levels of GIP and GLP-1 secretion. This reduction is more pronounced for GIP than for GLP-1, indicating a loss of acute insulinotropic activity in GIP.

Moreover, beyond their role in glucose regulation, both peptides have additional biological functions. For instance, GLP-1 has been shown to reduce appetite and food intake, potentially leading to long-term weight reduction, although similar effects for GIP are less confirmed in human studies. Additionally, GIP promotes triglyceride storage in white adipose tissue through mechanisms that extend beyond insulin secretion alone.

What This Means for Peptide Users

For individuals using peptides like GLP-1 or considering co-agonists targeting both GIP and GLP-1 receptors, this research underscores the importance of understanding these peptides' multifaceted roles. The diminished incretin effect in type 2 diabetes suggests that therapeutic strategies should consider enhancing the efficacy of both GIP and GLP-1 to achieve better glucose control. Furthermore, the potential for co-agonists targeting both pathways may offer a more comprehensive approach to managing metabolic diseases.

Limitations and Caveats

As a review paper, this study relies heavily on existing literature and does not present new experimental data. Consequently, it may not capture all recent findings or nuances in experimental methodologies. Additionally, the clinical relevance of some findings, such as GIP's role in triglyceride storage, is still under investigation and requires further validation through human studies.

How This Compares to Previous Research

This review builds upon previous research by providing a more detailed analysis of the physiological roles of GIP and GLP-1. It aligns with earlier findings on their insulinotropic effects but offers new insights into their divergent actions on glucagon secretion and additional biological functions. The emphasis on the reduced incretin effect in type 2 diabetes is consistent with previous studies, reinforcing the need for targeted therapeutic approaches.

Our Analysis

PeptideVault views this review as a valuable update to our understanding of GIP and GLP-1's roles in metabolic health. While it synthesizes existing knowledge effectively, the reliance on previously published data means that some aspects may require further investigation through new experimental studies. The implications for peptide therapy are promising but should be interpreted with caution due to ongoing research needs.

Key Takeaways

  • Diminished Incretin Effect: Type 2 diabetic patients exhibit a reduced incretin effect, particularly in GIP.
  • Therapeutic Potential: Co-agonists targeting both GIP and GLP-1 receptors may offer superior efficacy for metabolic disease management.
  • Further Research Needed: Additional studies are required to fully understand the clinical implications of GIP's role in triglyceride storage and other biological functions.

Original Source

Citation: Nauck Michael A, Quast Daniel R, Wefers Jakob et al. (2021). The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.. Diabetes, obesity & metabolism. DOI: 10.1111/dom.14496

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Примечание Редактора

Этот анализ был написан командой исследований Peptide Contacts для того, чтобы сделать сложные выводы доступными для сообщества исследований Peptide. Мы призываем читателей проверить исходную статью для полной методологии и данных. Для получения дополнительной информации о GIP, изучите наши руководства по исследованию.

Цитирование

Nauck Michael A, Quast Daniel R, Wefers Jakob et al.. (2021). The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.14496

Просмотр полного текста на PubMed

Связанные статьи

Исследуйте Дальнейшее

Это содержание основано на рецензированных исследованиях для образовательных целей только. Это не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед использованием каких-либо терапий на основе Peptide.